Navigation Links
First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
Date:1/13/2009

SAN CARLOS, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that dosing has started in a Phase 2 clinical trial of NKTR-102 in platinum-resistant ovarian cancer. Regulatory approvals have also been obtained and dosing will begin shortly in two additional trials: a randomized Phase 2 study to evaluate NKTR-102 versus irinotecan in second-line colorectal cancer patients with the KRAS gene mutation, and a Phase 2 study in metastatic breast cancer. Nektar has also received Institutional Review Board (IRB) approval for a Phase 2 cervical cancer study of NKTR-102.

"NKTR-102 is an excellent example of how Nektar's advanced polymer conjugate technology platform allowed us to precisely modify a cytotoxic agent with sub-optimal pharmacokinetics and enhance its therapeutic profile," said Randall Moreadith, M.D., Ph.D., Senior Vice President and Chief Development Officer of Nektar. "We are excited to have dosed our first patient in the start of our expanded Phase 2 clinical development program. NKTR-102 is a novel oncolytic that has the potential to dramatically expand therapeutic options for oncologists and improve survival rates for patients with a variety of cancers."

Using its proprietary polymer conjugate technology platform, Nektar is the first company to have created a small molecule PEGylated drug conjugate that has demonstrated therapeutic activity in patients. In addition to the Phase 2 clinical studies in breast, ovarian, cervical and colorectal cancers, a Phase 2a study evaluating NKTR-102 in combination with cetuximab has completed enrollment and full results of this study are expected to be available in the first half of 2009.

About the NKTR-102 Phase 2 Study Designs

The NKTR-102 Phase 2 randomized trial will evaluate the efficacy
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 2009 Marks 50 Years of Innovative Firsts for Instrumentation Laboratory
2. Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase
3. The IN VIVO Blog Selects First Annual Deal of the Year
4. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
5. RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants
6. First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform
7. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
8. USC researchers derive first embryonic stem cells from rats
9. ASP Announces Availability of EVOTECH(TM) Endoscope Cleaner and Reprocessor - First Commercially Available System to Eliminate Manual Cleaning of Endoscopes
10. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
11. Bioamber announces worlds first bio-based succinic acid plant: helping to reduce dependence on fossil fuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... three large odour control systems for waste water treatment plants ... are consistent with the market resurgence in North ... CEO. "After a difficult period of restraint in our core ... sales growth. Our lower cost structure, technology improvements and supply ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
(Date:9/1/2014)... September 01, 2014 The global ... million by 2019 from $1,070.7 million in 2014, ... to 2019. The global oligonucleotide synthesis market is ... applications, end users, and geography. The synthesized oligonucleotides ... rate in the oligonucleotide synthesis market during the ...
(Date:8/31/2014)... (PRWEB) September 01, 2014 Available ... lighting needs for research and cultivation of a ... by Valoya’s proprietary LEDs with proven patented and ... ensures uncompromised light uniformity in critical applications in ... white LEDs. , “Our customers have a large ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... AMSTERDAM, November 11 Amsterdam Molecular,Therapeutics (Euronext: AMT), ... today that it has successfully treated Duchenne muscular dystrophy,(DMD) ... The proof of,concept studies were performed in collaboration with ... Sapienza, Italy) and demonstrated,effectiveness in the heart as well ...
... THE WOODLANDS, Texas, Nov. 10 Today, US ... , executive vice president and general counsel, will be ... http://www.newscom.com/cgi-bin/prnh/20091110/DA08765 ) , Watts has had a long ... worked with US Oncology providing legal services and consultation as ...
... , ST. LOUIS, Nov. 10 At the Board of ... dividend of $.145 per share, an 11.5% increase over the ... 2009 to shareholders of record on December 1, 2009. , ... Life Science and High Technology company. Our chemical and biochemical ...
Cached Biology Technology:AMT Successful in Preclinical Treatment of DMD 2AMT Successful in Preclinical Treatment of DMD 3US Oncology Announces Retirement of General Counsel Phil Watts 2
(Date:9/2/2014)... professional baseball pitchers with poor core stability are more likely ... because of injury than are pitchers who have good control ... the study, 347 pitchers were assessed for lumbopelvic control during ... they raised a leg to step up were up to ... cumulative, not consecutive during the season than were ...
(Date:9/2/2014)... issue of The FASEB Journal , ... the leading cause of blindness in adults, diabetic ... advance involves quantifying the early molecular changes caused ... Using new probes developed by scientists, they were ... diabetic retinopathy. , "My goal is to establish ...
(Date:9/2/2014)... September 2, 2014 Best-selling author Sam Kean stops ... the Megalodon, the 50-foot super shark that, despite what ... extinct. Learn all about it at http://youtu.be/KhFygIoW_MA . ... Tales of Madness, Love and the History of the ... getting the Reactions treatment in a 10-episode video series ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... pet rescue organizations are growing in number, working ... Although the majority of these organizations operate out ... winning high visibility for placing their pooches. , ... of the American Sociological Association (ASA) in Philadelphia, ...
... threatened by exotic species of the moon jellyfish being ... Using genetic data and computer simulations of ocean currents ... South Wales and the University of California, Davis, have ... naturally, according to a report in today's Proceedings of ...
... new study has found that the allergenicity of peanut ... process. Researchers from North Carolina A&T University report their ... American Society for Microbiology. , "Due to the wide ... snacks and even soups there is a need to ...
Cached Biology News:Virtual animal shelters ?How the Internet is transforming the experience of pet adoptions 2Ships bring alien jellyfish invaders to our shores 2
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
...
Request Info...
Biology Products: